Toronto, Canada – DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a leading generative AI healthcare solutions company, is thrilled to announce the debut of PalGPT.ai (https://palgpt.ai), a state-of-the-art generative AI brain health solution powered by OpenAI’s ChatGPT. PalGPT.ai is DiagnaMed’s latest commercial offering from its Health GenAI division, dedicated to developing and implementing a range of customizable and ready-made generative AI applications that support the healthcare industry in enhancing patient outcomes, operational workflows, and overall efficiency.
PalGPT.ai has been meticulously designed to engage in natural, human-like conversations and serve as a personal AI companion for individuals seeking privacy and meaningful connections. Through concise text messages delivered via SMS chat, PalGPT.ai becomes an integral part of daily life. It offers practical advice, emotional support, self-improvement tips, and valuable resources. Moreover, PalGPT.ai provides a confidential space for sharing thoughts, feelings, beliefs, experiences, memories, and dreams. After signing up for the service, users receive personalized messages based on their previous interactions. The platform also sends daily check-in messages to engage users and offers cancellation options via text.
Interested individuals can experience PalGPT.ai with a 3-day free trial by visiting https://palgpt.ai.
Fabio Chianelli, Chairman of DiagnaMed, expressed his enthusiasm for the launch, stating, “We are delighted to introduce our second generative AI-powered product, PalGPT.ai, as a potential tool for improving overall brain health. By developing OpenAI ChatGPT-powered solutions, we aim to integrate them into our CERVAI™ generative AI brain health platform and make them accessible to the mass market, empowering individuals to achieve their brain health goals.”
PalGPT.ai is an outcome of DiagnaMed’s extensive knowledge and development experience, incorporating features from its proprietary generative AI brain health platform, CERVAI™. The solution caters to patients, licensed medical professionals, hospitals, and life science companies, and will be seamlessly integrated into the comprehensive CERVAI™ platform, offering a complete suite of brain health solutions.
According to Market.us, the healthcare market’s adoption of generative AI is expected to reach approximately USD 17 billion by 2032. This growth is driven by automation’s increasing prevalence in drug discovery, medical imaging, personalized medical interventions, hospitals, and clinical decision support systems. DiagnaMed, with its two divisions – CERVAI™ and Health GenAI, is strategically positioned to become a leader in generative AI solutions for the healthcare market, meeting the evolving needs of industry stakeholders.
